Development of a 1:1-binding biparatopic anti-TNFR2 antagonist by reducing signaling activity through epitope selection

Development of a 1:1-binding biparatopic anti-TNFR2 antagonist by reducing signaling activity through epitope selection

Abstract Conventional bivalent antibodies against cell surface receptors often initiate unwanted signal transduction by crosslinking two antigen molecules. Biparatopic antibodies (BpAbs) bind to two different epitopes on the same antigen, thus altering crosslinking ability. In this study, we develop...

Full description

Bibliographic Details
Main Authors: Hiroki Akiba, Junso Fujita, Tomoko Ise, Kentaro Nishiyama, Tomoko Miyata, Takayuki Kato, Keiichi Namba, Hiroaki Ohno, Haruhiko Kamada, Satoshi Nagata, Kouhei Tsumoto
Format: Article
Language:English
Published: Nature Portfolio 2023-09-01
Series:Communications Biology
Online Access:https://doi.org/10.1038/s42003-023-05326-8

Internet

https://doi.org/10.1038/s42003-023-05326-8

Similar Items